Summary: In June's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) consider the European Medicines Agency's decision to amend the licence for omega-3 fatty acid medicines so that they will no longer be authorised for secondary prevention after myocardial infarction. The editors also review ospemifene, a new medicine for the management of vulvar and vaginal atrophy and discuss a case of delusional infestation in the treatment of ADHD with atomoxetine. <p>Read the full issue: https://dtb.bmj.com/content/57/6.</p>
